Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.
about
Induced Pluripotent Stem Cell as a New Source for Cancer ImmunotherapyApplications of iPSCs in Cancer ResearchAdvances in cellular technology in the hematology field: What have we learned so far?Advances and Challenges on Cancer Cells Reprogramming Using Induced Pluripotent Stem Cells TechnologiesTechnical Considerations for the Generation of Adoptively Transferred T Cells in Cancer ImmunotherapyEstablishment of specific cytotoxic T lymphocyte culture system and its inhibitory effect on ovarian cancer.Avoiding immunological rejection in regenerative medicine.Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice.A human microglia-like cellular model for assessing the effects of neurodegenerative disease gene variants.
P2860
Q26750579-9C8C5E44-7ED3-4F5A-A4D3-D8112DBD3751Q26798036-18863953-3B7D-4DF5-8A62-9BA92F10A243Q26853179-6DEF8A0B-1FB5-4FB1-BE3B-3435FFE2EE71Q28071879-E7FEB60F-DBB4-4F23-B803-F07E3666B297Q28073563-681C0656-5891-48DE-9ED6-B67F6E4B3B0AQ37407315-F913BC38-CC83-4E77-A813-3F96B491B645Q38453650-90761159-6FE0-4C79-8039-A3DEFD00E395Q41337940-042DF2A7-7E22-43A2-9A15-BB7684A3DEB6Q47269263-3EBCEE81-5EAE-4522-9C16-C5957B1C4BE1
P2860
Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.
@en
type
label
Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.
@en
prefLabel
Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.
@en
P2093
P2860
P356
P1476
Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.
@en
P2093
Patty Sachamitr
Paul Jonathan Fairchild
Simon Hackett
P2860
P356
10.3389/FIMMU.2014.00176
P577
2014-04-17T00:00:00Z